Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Advertisement

Related Content

2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban
Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban; Will Not Pursue Anticoagulants
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib
Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
Advertisement
UsernamePublicRestriction

Register

SC077913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel